PNI is a global leader in technology and solutions for developing RNA, DNA, CRISPR, small molecule drugs, COVID vaccines and therapeutics rapidly taking ideas to patients.

Precision NanoSystems Announces Partnership with Fujifilm for the Development and GMP Manufacturing of Nanoparticle Based Therapeutics


Read the Full Press Release

mRNA Webinar

Non-Viral Delivery of Self-Amplifying mRNA Vaccines

Dr. Andrew Geall 
March 31, 2020 
8:30am PDT 
Registration Link

Formulation Solutions Formulation Solutions Formulation Solutions
Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations.
Optimize a wide range of nanomedicine formulations with the NanoAssemblr® Ignite or the Blaze  depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Scalable manufacturing is a significant challenge to making revolutionary medicine and  Clinical Solution  is ready to assist you in your nanoparticle manufacturing process development.
Formulation Solutions Formulation Solutions Formulation Solutions
You're In Good Company


  • “The NanoAssemblr® Blaze™ from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrument has saved us time, effort and precious materials.” - Muthusamy Jayaraman Senior Director, Head of Non-Viral Delivery at CRISPR Therapeutics
  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use."  - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."- Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines"  - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

NxGen logo


Our exclusive NxGen technology uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales. NxGen technology is at the heart of the NanoAssemblr® family, which provides manufacturing of nanoparticles at different scales suitable for all stages of nanomedicine development.

 Learn More.


Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine. 
of top pharmaceutical companies work with PNI

instruments are installed


biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly in the drug development process. Contact our Business Development Team.






Precision NanoSystems Announces Partnership with Fujifilm

James Taylor, Co-Founder and CEO of PNI said, “We are thrilled to work with Fujifilm to enable our technology in support of clinical clients as they progress their therapeutic programs from the laboratory to the clinic and commercial."

Precision NanoSystems to Launch the Revolutionary Ignite™


Precision NanoSystems (PNI) a global leader of innovative solutions is pleased to introduce our newest member of the Nanoassemblr® Platform: the Ignite™ available October 15, 2019.

Clinical Solutions Platform Launch


“Clinical Solutions is designed to provide a one-stop-shop for all nanomedicine clinical development needs, such as sourcing GMP excipients, developing analytical methods, building Quality Management Systems or accessing experienced Contract Manufacturing Organizations,” Precision NanoSystems' CFO, Euan Ramsay

Upcoming Events See All

Resource Center

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More 阅读更多

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More 阅读更多

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More 阅读更多 PDF
Resource Center 资源中心

Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.